A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Safety and Tolerability of Oral PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis

Administered By

Contributors

Start/End

  • January 27, 2022 - January 31, 2024